LONDON—GlaxoSmithKline plans to split into two businesses—one for prescription drugs and vaccines, the other for over-the-counter products—after forming a new joint venture with Pfizer’s consumer health division.
The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year.
